Secretary of Health Robert F. Kennedy Jr. announced on the Joe Rogan podcast on February 27, 2026 that approximately 14 of the 19 peptides that the FDA placed in Category 2 in 2023 will return to Category 1.[1][2] Category 2 prohibited compounding pharmacies from producing these peptides for patients.[1][4] Category 1 classification will allow licensed compounding pharmacies to legally prepare them with a doctor's prescription.[1][2] Kennedy stated that the original classification into Category 2 occurred without legitimate safety signals.[1][2] These peptides are not fully FDA approved as drugs and require medical supervision.[2][4] Restrictions have previously created a gray market for substandard products without quality control.[2][4] The announcement relates to peptides used in regenerative medicine, anti-aging and metabolic health.[2]